Sepsis: The evolution in definition, pathophysiology, and management

被引:282
作者
Gyawali, Bishal [1 ]
Ramakrishna, Karan [1 ]
Dhamoon, Amit S. [1 ]
机构
[1] SUNY Upstate Med Univ, Dept Med, 750 East Adams St, Syracuse, NY 13210 USA
关键词
Critical care; emergency medicine; infectious diseases; hematology; GOAL-DIRECTED RESUSCITATION; CRITICALLY-ILL PATIENTS; EARLY LACTATE CLEARANCE; NECROSIS-FACTOR-ALPHA; INTENSIVE-CARE UNITS; SEPTIC SHOCK; FLUID RESUSCITATION; ORGAN FAILURE; SERUM LACTATE; PLASMINOGEN-ACTIVATOR;
D O I
10.1177/2050312119835043
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
There has been a significant evolution in the definition and management of sepsis over the last three decades. This is driven in part due to the advances made in our understanding of its pathophysiology. There is evidence to show that the manifestations of sepsis can no longer be attributed only to the infectious agent and the immune response it engenders, but also to significant alterations in coagulation, immunosuppression, and organ dysfunction. A revolutionary change in the way we manage sepsis has been the adoption of early goal-directed therapy. This involves the early identification of at-risk patients and prompt treatment with antibiotics, hemodynamic optimization, and appropriate supportive care. This has contributed significantly to the overall improved outcomes with sepsis. Investigation into clinically relevant biomarkers of sepsis are ongoing and have yet to yield effective results. Scoring systems such as the sequential organ failure assessment and Acute Physiology and Chronic Health Evaluation help risk-stratify patients with sepsis. Advances in precision medicine techniques and the development of targeted therapy directed at limiting the excesses of the inflammatory and coagulatory cascades offer potentially viable avenues for future research. This review summarizes the progress made in the diagnosis and management of sepsis over the past two decades and examines promising avenues for future research.
引用
收藏
页数:13
相关论文
共 110 条
[61]   2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference [J].
Levy, MM ;
Fink, MP ;
Marshall, JC ;
Abraham, E ;
Angus, D ;
Cook, D ;
Cohen, J ;
Opal, SM ;
Vincent, JL ;
Ramsay, G .
CRITICAL CARE MEDICINE, 2003, 31 (04) :1250-1256
[62]   The influence of esmolol on septic shock and sepsis: A meta-analysis of randomized controlled studies [J].
Liu, Ping ;
Wu, Qi ;
Tang, Yu ;
Zhou, Zhiguo ;
Feng, Malong .
AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2018, 36 (03) :470-474
[63]   Efficacy of coupled plasma filtration adsorption ( CPFA) in patients with septic shock: A multicenter randomised controlled clinical trial [J].
Livigni, Sergio ;
Bertolini, Guido ;
Rossi, Carlotta ;
Ferrari, Fiorenza ;
Giardino, Michele ;
Pozzato, Marco ;
Remuzzi, Giuseppe .
BMJ OPEN, 2014, 4 (01)
[64]   Efficacy of red blood cell transfusion in the critically ill: A systematic review of the literature [J].
Marik, Paul E. ;
Corwin, Howard L. .
CRITICAL CARE MEDICINE, 2008, 36 (09) :2667-2674
[65]   Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock A Retrospective Before-After Study [J].
Marik, Paul E. ;
Khangoora, Vikramjit ;
Rivera, Racquel ;
Hooper, Michael H. ;
Catravas, John .
CHEST, 2017, 151 (06) :1229-1238
[66]   Stress hyperglycemia: an essential survival response! [J].
Marik, Paul E. ;
Bellomo, Rinaldo .
CRITICAL CARE, 2013, 17 (02)
[67]  
Marik PE., 2013, CRIT CARE MED, V41, P292
[68]  
Marshall JC, 1995, CLIN TRIALS TREATMEN, P327
[69]  
Marshall John C, 2004, Crit Care Med, V32, pS513, DOI 10.1097/01.CCM.0000143119.41916.5D
[70]  
Mesters RM, 1996, THROMB HAEMOSTASIS, V75, P902